Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19.

Despite the small sample size, a clear trend can be discerned between AT-9010 in AMs and AT-273 in plasma and ELF in four subjects who received bemnifosbuvir 825 mg twice daily, and all had quantifiable AM AT-9010 in the 4–5 h samples (Figure 4 ).

also in 19,460 other papers